Global Alpha 1 Antitrypsin Deficiency Treatment Market Report 2021-2027 –

Global Alpha 1 Antitrypsin Deficiency Treatment Market Report 2021-2027 –

Global Alpha 1 Antitrypsin Deficiency Treatment Market Report 2021-2027 –

DUBLIN–(BUSINESS WIRE)–The “Alpha 1 Antitrypsin Deficiency Treatment – Global Market Trajectory & Analytics” report has been added to’s offering.

Global Alpha 1 Antitrypsin Deficiency Treatment Market to Reach $2.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Alpha 1 Antitrypsin Deficiency Treatment estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2027, growing at a CAGR of 8.9% over the analysis period 2020-2027.

Augmentation Therapy, one of the segments analyzed in the report, is projected to record a 9.7% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Bronchodilator segment is readjusted to a revised 9.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $463.6 Million, While China is Forecast to Grow at 8.3% CAGR

The Alpha 1 Antitrypsin Deficiency Treatment market in the U.S. is estimated at US$463.6 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$493.1 Million by the year 2027 trailing a CAGR of 8.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Corticosteroids Segment to Record 7.7% CAGR

In the global Corticosteroids segment, USA, Canada, Japan, China and Europe will drive the 7.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$189.6 Million in the year 2020 will reach a projected size of US$319.9 Million by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$328.4 Million by the year 2027.

Key Topics Covered:




  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS (Total 46 Featured):

  • Abeona Therapeutics Inc.
  • Applied Genetic Technologies Corporation
  • Arrowhead Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • CSL Behring
  • Curaxys
  • GlaxoSmithKline PLC
  • Grifols International SA
  • Kamada Ltd.
  • Pfizer, Inc.
  • ProBioGen AG
  • ProMetic Life Sciences, Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.




  • United States
  • Canada
  • Japan
  • China
  • Europe
  • France
  • Germany
  • Italy
  • United Kingdom
  • Spain
  • Russia
  • Rest Of Europe
  • Asia-Pacific
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest Of Latin America
  • Middle East
  • Iran
  • Israel
  • Saudi Arabia
  • United Arab Emirates
  • Rest Of Middle East
  • Africa


  • Total Companies Profiled: 46

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900